When the Watch Beeps: Managing Device-Detected AF - Dr Emma Svennberg - DaRe2THINK Webinar скачать в хорошем качестве

When the Watch Beeps: Managing Device-Detected AF - Dr Emma Svennberg - DaRe2THINK Webinar

DaRe2THINK, a national primary care trial sponsored by the NIHR, University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, welcome you to the Continuing Professional Development (CPD) webinar with Dr Emma Svennberg. This talk is part of a series hosted by the DaRe2THINK trial to provide information to allied healthcare professionals and general practice staff across UK, on cardiovascular health in primary care. Dr. Emma Svennberg is an Assistant Professor, Electrophysiologist, and Head of Specialty Training at the Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden. Her primary research interests focus on atrial fibrillation (AF) screening, particularly systematic approaches, where she has played a key role in the large population-based screening studies STROKESTOP I & II. Dr. Svennberg has been recognized with the Swedish Society of Cardiology Research Award twice and holds fellowships with the European Society of Cardiology (ESC) and the European Heart Rhythm Association (EHRA). She was a founding member and later President of the Swedish branch of Cardiologists of Tomorrow. In 2024, she was elected Treasurer of the EHRA board and currently serves on its Executive Board. She was also part of the ESC 2024 Task Force for the Atrial Fibrillation Guidelines. DaRe2THINK This webinar is hosted by DaRe2THINK, a primary care clinical trial sponsored by the NIHR, University of Birmingham and University Hospitals Birmingham NHS Foundation Trust. DaRe2THINK is a transformational project that will test a new way of running clinical trials at General Practices in the NHS. The trial will use health information already collected in the NHS to reduce the time taken for research, both for the patients and NHS staff. This will allow the NHS to reach new and larger groups of patients that could benefit from new treatments opening the possibility of research to populations that would not have previously taken part.